123 studies found for:    IGF1R
Show Display Options
Rank Status Study
1 Completed Retrospective Study Evaluating IGF1R And p95HER2 as Prognostic Factors in Non Small Cell Lung Cancer (NSCLC)
Condition: Non Small Cell Lung Cancer
Intervention: Genetic: Protein expression by immunohistochemistry and immunofluorescence
2 Completed Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors
Condition: Solid Tumors
Intervention: Drug: BIIB022
3 Not yet recruiting Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma
Conditions: Malignant Glioma;   Neoplasms
Interventions: Drug: IGF-1R/AS ODN; Surgery with tissue harvest and implantation 10 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 24 hours.;   Drug: IGF-1R/AS ODN; Surgery with tissue harvest and implantation 10 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 48 hours.;   Drug: IGF-1R/AS ODN; Surgery with tissue harvest and implantation of 20 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 24 hours.;   Drug: IGF-1R/AS ODN; Surgery with tissue harvest and implantation of 20 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 48 hours.
4 Completed Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: AVE1642;   Drug: Velcade
5 Suspended Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors
Condition: Advanced Refractory Solid Tumors
Intervention: Drug: PL225B
6 Terminated Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: AVE1642;   Drug: Fulvestrant
7 Terminated
Has Results
IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery
Conditions: Recurrent Adrenocortical Carcinoma;   Stage III Adrenocortical Carcinoma;   Stage IV Adrenocortical Carcinoma
Interventions: Biological: IMC-A12;   Drug: mitotane
8 Withdrawn Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: IGF-1R inhibitor OSI-906;   Drug: erlotinib hydrochloride;   Drug: goserelin;   Drug: letrozole
9 Completed A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: BIIB022 With Paclitaxel and Carboplatin
10 Completed A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors
Conditions: Askin's Tumors;   Desmoplastic Small Round Cell Tumors;   Estraosseous Ewing's Tumor;   Ewing's Family Tumor;   Ewing's Sarcoma;   Primitive Neuroectodermal Tumors (PNETs);   Sarcoma
Intervention: Drug: AMG 479
11 Active, not recruiting Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
Conditions: Adult Hepatocellular Carcinoma;   Advanced Adult Hepatocellular Carcinoma;   Localized Non-Resectable Adult Liver Carcinoma;   Recurrent Adult Liver Carcinoma
Interventions: Biological: Cixutumumab;   Other: Laboratory Biomarker Analysis;   Drug: Sorafenib Tosylate
12 Terminated
Has Results
Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology
Conditions: Carcinoma, Squamous Cell;   Carcinoma, Adenosquamous;   Carcinoma, Large Cell;   Carcinoma, Non-Small-Cell Lung
Interventions: Drug: CP-751,871 (Figitumumab);   Drug: Carboplatin;   Drug: Paclitaxel
13 Completed A Study to Evaluate the Biological Activity of R1507 in Women With Operable Breast Cancer
Condition: Breast Cancer
Intervention: Drug: RG1507
14 Completed Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)
Condition: Hepatocellular Carcinoma
Interventions: Drug: BIIB022;   Drug: Sorafenib
15 Recruiting Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R
Conditions: Breast Cancer;   Brain Cancer;   Gastrointestinal Cancers;   Genitourinary Cancers;   Gynecologic Cancers;   Head and Neck Cancers;   Melanoma;   Thoracic Cancers
Intervention: Drug: IGF-Methotrexate
16 Completed A Study of the IGF-1R Inhibitor AXL1717 in Combination With Gemcitabine HCL and Carboplatin to Treat Non-small-cell Lung Cancer (NSCLC)
Condition: Non Small Cell Lung Cancer
Intervention: Drug: AXL1717
17 Active, not recruiting Studying Tissue Samples From Women With Breast Cancer Who Were Treated on Clinical Trial NCCTG-N9831
Condition: Breast Cancer
Intervention: Other: diagnostic laboratory biomarker analysis
18 Active, not recruiting
Has Results
Cisplatin and Etoposide With or Without Vismodegib or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Conditions: Extensive Stage Small Cell Lung Cancer;   Recurrent Small Cell Lung Cancer
Interventions: Biological: cixutumumab;   Drug: vismodegib;   Drug: cisplatin;   Drug: etoposide
19 Completed Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
Condition: Recurrent Small Cell Lung Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Linsitinib;   Other: Pharmacological Study;   Drug: Topotecan Hydrochloride
20 Active, not recruiting Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Conditions: Gastrin-Producing Neuroendocrine Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Pancreatic Polypeptide Tumor;   Paraganglioma;   Recurrent Digestive System Neuroendocrine Tumor G1;   Recurrent Merkel Cell Carcinoma;   Recurrent Pancreatic Neuroendocrine Carcinoma;   Regional Digestive System Neuroendocrine Tumor G1;   Somatostatin-Producing Neuroendocrine Tumor;   Stage III Merkel Cell Carcinoma;   Stage IV Merkel Cell Carcinoma;   Thyroid Gland Medullary Carcinoma
Interventions: Biological: Cixutumumab;   Drug: Everolimus;   Other: Laboratory Biomarker Analysis;   Drug: Octreotide Acetate;   Other: Pharmacological Study

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years